[Infection prophylaxis in patients with hematological malignancies (I)--Successful prophylaxis of Pneumocystis carinii pneumonitis with sulfamethoxazole-trimethoprim].
In a retrospective study to evaluate the efficacy of sulfamethoxazole-trimethoprim (SMX-TMP) for the prevention of Pneumocystis carinii pneumonitis, we studied 1760 patients wit hematological malignancies over a twenty-year period (1970-1989). 449 patients received oral SMX-TMP, most of all received 400 mg of SMX and 80 mg of TMP twice per day. None of the patients receiving SMX-TMP developed P carinii pneumonitis, whereas twenty-six (2.0%) of the 1311 patients who did not receive SMX-TMP developed P carinii pneumonitis (p less than 0.01). We found that the SMX-TMP was very effective in the prevention of P carinii pneumonitis in patients with hematological malignancies, and was well tolerated.
Moriuchi
Y
Y
Department of Internal Medicine, Nagasaki University School of Medicine.
Kamihira
S
S
Satoh
T
T
Yanagisako
T
T
Miyazaki
Y
Y
Nagai
K
K
Murata
K
K
Tokunaga
S
S
Maeda
T
T
Atogami
S
S
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002648:Child; D004338:Drug Combinations; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D008875:Middle Aged; D009894:Opportunistic Infections / Q000209:etiology / Q000517:prevention & control*; D011020:Pneumonia, Pneumocystis / Q000209:etiology / Q000517:prevention & control*; D011292:Premedication; D013420:Sulfamethoxazole / Q000008:administration & dosage*; D014295:Trimethoprim / Q000008:administration & dosage*
D004338:Drug Combinations; D014295:Trimethoprim; D013420:Sulfamethoxazole